0001127602-17-026934.txt : 20170905 0001127602-17-026934.hdr.sgml : 20170905 20170905152627 ACCESSION NUMBER: 0001127602-17-026934 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170831 FILED AS OF DATE: 20170905 DATE AS OF CHANGE: 20170905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stonehouse Jon P CENTRAL INDEX KEY: 0001385496 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 171068568 MAIL ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2017-08-31 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001385496 Stonehouse Jon P 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 1 President & CEO Emp. Stock Option (Right to Buy) 12.16 2017-08-31 4 A 0 40710 0 A 2017-08-31 2025-01-01 Common Stock 40710 40710 D On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded to the reporting person in January 2015 has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. /s/ Alane P. Barnes, by power of attorney 2017-09-05